Search
Abcellera Biologics Inc
ABCLAdd to Watchlist
12.310USD
-0.340-2.69%
Close 09-22 16:00（ET）
3.76BMarket Cap
LossP/E TTM
After-hours 17:00 (ET)12.340USD+0.025+0.20%
After-hours 17:00 (ET)Abcellera Biologics Inc (ABCL) Stock Price Target & Forecast
Analyst Rating
Based on 9 analysts giving stock ratings to Abcellera Biologics Inc in the past month.
Buy
1 Strong Buy
8 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
17.125USD+35.38%
ABCL Analyst Recommendation Trends
In the current month, ABCL has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ABCL average Analyst price target in the last month is 17.125.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
1
1
1
1
1
1
8
8
7
7
6
6
6
6
0
0
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
9
9
9
8
8
8
8
ABCL Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, ABCL EPS is projected to reach -0.170 in FY2026Q3, following reported EPS of -0.181 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.17
-0.20
-0.14
-0.17
-0.17
Actual
-0.03
-0.14
-0.18
--
--
Surprise
+82.85%
+27.23%
-26.98%
--
--
FAQs
What is Abcellera Biologics Inc's expected revenue for the next quarter?
Abcellera Biologics Inc's expected revenue is 5.32M.
What is Abcellera Biologics Inc's price target?
Analysts forecast that Abcellera Biologics Inc's price target is USD 17.12, with the highest forecast at USD 30.00 and the lowest forecast at USD 9.00.
How have Abcellera Biologics IncABCL's recent earnings per share performed?
The market expectation was USD -0.18, while Abcellera Biologics IncABCL's earnings per share (EPS) for the previous quarter was USD -0.14. EPS for the next quarter is expected at USD -0.17.
What is the analyst rating for Abcellera Biologics Inc?
Based on the ratings of Abcellera Biologics Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.